Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03541499 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults
A Phase 2 study of Pertussis and Pertussis Immunisation, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03541499 is a Phase 2 study of Pertussis and Pertussis Immunisation that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 50 participants, below the 38,926-participant average among 14 other Pertussis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03541499, a Phase 2 study of Pertussis and Pertussis Immunisation, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, partially blind, placebo controlled, clinical trial evaluating a single intranasal dose of BPZE1 in healthy adults. The study will evaluate a lyophilized formulation of the product, with the goal of testing for the optimal dose for subsequent clinical trials. Fifty healthy adults, 18-49 years of age will be randomized to one of the four following treatment groups in a 3:3:3:1 ratio: 10\^7 colony forming units (CFU) of BPZE1 administered by VaxINator device, 10\^9 CFU of BPZE1 administered by VaxINator device, placebo administered by VaxINator device, 10\^9 CFU of BPZE1 administered by needleless tuberculin syringe. Study duration will be approximately 12 months with a subject participation duration of approximately 6 months. The primary objective of this study is to assess the safety and tolerability of a single intranasal dose of either 10\^7 or 10\^9 CFU of lyophilized BPZE1 vaccine.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL BPZE1
Study Locations (1)
Tennessee
- Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-10-23 |
| Est. Completion | 2020-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03541499
The ClinicalTrials.gov registry entry for NCT03541499 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 38,926-participant average among 14 other Pertussis trials with a reported enrollment target (100% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pertussis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03541499 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT03541499 about?
NCT03541499 is a clinical study titled "Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults". This is a randomized, partially blind, placebo controlled, clinical trial evaluating a single intranasal dose of BPZE1 in healthy adults. The study will evaluate a lyophilized formulation of the product, with the goal of testing for the optimal dose for subsequent clinical trials. Fifty healthy adul...
What is the current status of trial NCT03541499?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2018-10-23. Estimated completion is 2020-05-15.
What conditions does trial NCT03541499 study?
This clinical trial studies the following conditions: Pertussis, Pertussis Immunisation.
What interventions are being tested in trial NCT03541499?
The interventions under investigation include: Placebo (OTHER), BPZE1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03541499?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03541499 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pertussis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pentavalent DTaP-Hep B-IPV
COMPLETED · Phase 2
-
Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants
COMPLETED · Phase 2
-
Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine
COMPLETED
-
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
COMPLETED · Phase 4
-
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
COMPLETED · Phase 4
-
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.